- ASC30 demonstrated placebo-adjusted weight loss of up to 7.7% in a recently completed 13-week U.S. Phase II study in participants with obesity or overweight, with better gastrointestinal ...

INTENT Biologics, a clinical-stage biotechnology company developing PEP Biologic as the first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, ...

The first healthy volunteers have been dosed in an early clinical trial testing NRG5051, a disease-modifying therapy for ALS ...

CBX-12 targets tumor cells with exatecan, offering potential for patients ineligible for antigen-targeted therapies. Phase 2 trial evaluates CBX-12's safety, tolerability, and efficacy in ...